IBB 技术面看涨，交投于 21 周均线上方，动能指标（RSI、MACD）为正。
逐段跳播
接下来看市场的关键领域，我想分享我对医疗保健的看法，而这一走势的主要受益者之一是IBB基金。这是一只生物科技交易所交易基金（ETF），你可以看到它有能力再次站上其21周移动平均线。
我们的相对强弱指数为正值，MACD指标也为正值，我们会更深入地探讨这个领域，但我提到的所有领域，尤其是软件、半导体，现在还有生物科技。这些领域之所以处于前沿，原因还是在于，半导体在高利率环境中通常表现不佳，生物科技也是如此。
通常会有一种避险情绪，但这三个领域的主要驱动力是人工智能的创新和新产品，我们会在讨论中谈到这一点。
Moving on to key areas of the market, I would like to share my thoughts on healthcare, and one of the main beneficiaries of that movement is the IBB fund. This is a biotechnology exchange-traded fund (ETF), and you can see it is in a position to trade again above its 21-week moving average .
We have a positive Relative Strength Index and a positive MACD indicator, and we will delve deeper into this area, but all the areas I mentioned, especially software, semiconductors and now biotechnology.
The reason these fields are at the forefront is that, again, semiconductors don't usually do well in a high-interest-rate environment, and the same is true for biotechnology. There is usually a sense of risk aversion, but the main driver for these three areas is innovation in artificial intelligence and new products, and we will address this as we talk.
这个频道对 $IBB 的历次判断
StockCharts TV 在这只股票上只有这一条判断。